Iron deficiency syndromes are the basis of a personalized approach to the treatment of anemia in pediatric practice


Cite item

Full Text

Abstract

The erythron’s physiological function is possible only with the normal bone marrow, adequate renal production of erythropoietin and sufficient supply of substrate (iron, protein) to erythroid bone marrow progenitor cells. Any defects of these factors can lead to the development of anemia. Iron deficiency is one of the most common causes of anemia in children. The causes of iron-deficiency erythropoiesis and anemia are different and are called iron-deficiency syndromes (IDS). Allocate absolute iron deficiency, a functional deficiency of iron, iron sequestration and hereditary IDS. Absolute iron deficiency leads to iron deficiency anemia (IDA), iron sequestration to anemia of inflammation, and individual mutations of genes encoding iron metabolism lead to hereditary forms of IDA. In clinical practice, the cause of anemia can be either one iron deficiency syndrome, or a combination of several IDS at once. Complex disorders of erythropoiesis and iron metabolism in patients with anemia can be the cause of resistance to oral iron. Differential diagnosis of the main IDS in individual case allows to choose the more optimal available therapeutic options.

Full Text

Restricted Access

About the authors

Valerii G. Demikhov

Pavlov Ryazan State Medical University

Email: demix777@ya.ru
Ryazan, Russia

Viacheslav V. Lebedev

Pavlov Ryazan State Medical University

Ryazan, Russia

Elena V. Demikhova

Pavlov Ryazan State Medical University

Ryazan, Russia

Yulia V. Abalenikhina

Pavlov Ryazan State Medical University

Ryazan, Russia

Andrei V. Dmitriev

Pavlov Ryazan State Medical University

Ryazan, Russia

References

  1. Lappin T The Cellular Biology of Erythropoietin Receptors. Oncologist 2003;(Suppl. 1): 15-8. doi: 10.1634/theoncologist.8-suppl_1-15
  2. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis. Transfusion 2012; 52: 1584-92.
  3. Румянцев А.Г., Морщакова Е.Ф., Павлов АД Эритропоэтин: биологические свойства, возрастная регуляция эритропоэза, клиническое применение. М.: ГЭОТАР-МЕД, 2003.
  4. Лебедев В.В., Демихов В.Г., Демихова Е.В. и др. Особенности выбора препарата для стартовой терапии железодефицитной анемии у детей. Врач. 2019; 30 (5): 19-26. doi: 10.29296/25877305-2019-05-04
  5. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306: 1520-8.
  6. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-7.
  7. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-42.
  8. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
  9. Демихов В.Г., Морщакова Е.Ф., Павлов АД. Роль гепцидина в патогенезе анемии хронических болезней. Гематология и трансфузиология. 2006; 5: 31-4.
  10. Finberg KE. Iron-refractory iron deficiency anemia. Semin Hematol 2009; 46: 378-86.
  11. Capra AP, Ferro E, CannavO L et al. A Child With Severe Iron-Deficiency Anemia and a Complex TMPRSS6 Genotype. Hematology 2017; 22 (9): 559-64.
  12. Bregman DB, Morris D, Koch TA et al. Hepcidin levels predict nonresponciveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88: 97-101.
  13. Аиари М., Демихов В.Г., Миров И.М. и др. Роль гепцидина при основных железодефицитных синдромах у беременных. Рос. медико-биологич. вестн. им. акад. И.П. Павлова. 2016; 24 (4): 96-103.
  14. Захарова И.Н., Тарасова И.С., Чернов В.М. и др. Ретикулоцитарные индексы в диагностике и контроле эффективности лечения железодефицитных состояний у детей. Педиатрическая фармакология. 2015; 12 (6).
  15. Лунякова М.А., Безнощенко А.Г., Демихов В.Г. и др. Уровни сывороточного эритропоэтина при анемиях у детей с острым лимфобластным лейкозом до начала химиотерапии. Онкогематология. 2008; 4.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies